27569995|t|Antidepressant -like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495
27569995|a|Clinical studies have shown that the muscarinic receptor antagonist scopolamine induces a potent and rapid antidepressant effect relative to conventional antidepressants. However, potential undesirable effects, including memory impairment, partially limit the use of scopolamine in psychiatry. In the present study, we propose to overcome these limitations and enhance the therapeutic effects of scopolamine via administration in combination with the group II metabotropic glutamate (mGlu) receptor antagonist, LY341495. Joint administration of sub-effective doses of scopolamine (0.03 or 0.1 mg/kg, i.p.) with a sub-effective dose of LY341495 (0.1 mg/kg, i.p.) induced a profound antidepressant effect in the tail suspension test (TST) and in the forced swim test (FST) in mice. This drug combination did not impair memory, as measured using the Morris water maze (MWM), and did not influence the locomotor activity of mice. Furthermore, we found that an AMPA receptor antagonist, NBQX (10 mg/kg), completely reversed the antidepressant-like activity of a mixture of scopolamine and LY341495 in the TST. However, this effect was not influenced by para-chlorophenylalanine (PCPA) pre-treatment, indicating a lack of involvement of serotonergic system activation in the antidepressant-like effects of jointly given scopolamine and LY341495. Therefore, the combined administration of low doses of the antimuscarinic drug scopolamine and the group II mGlu receptor antagonist LY341495 might be a new, effective and safe strategy in the therapy of depression.
27569995	0	14	Antidepressant	T103	UMLS:C0003289
27569995	32	43	scopolamine	T103	UMLS:C0036442
27569995	47	51	mice	T204	UMLS:C0025929
27569995	72	94	group II mGlu receptor	T103	UMLS:C0206529
27569995	95	105	antagonist	T103	UMLS:C1254351
27569995	106	114	LY341495	T103	UMLS:C0757826
27569995	115	131	Clinical studies	T062	UMLS:C0008972
27569995	152	171	muscarinic receptor	T103	UMLS:C0034826
27569995	172	182	antagonist	T103	UMLS:C1254351
27569995	183	194	scopolamine	T103	UMLS:C0036442
27569995	222	243	antidepressant effect	T033	UMLS:C0243095
27569995	269	284	antidepressants	T103	UMLS:C0003289
27569995	336	353	memory impairment	T038	UMLS:C0233794
27569995	382	393	scopolamine	T103	UMLS:C0036442
27569995	397	407	psychiatry	T091	UMLS:C0033873
27569995	424	429	study	T062	UMLS:C2603343
27569995	488	507	therapeutic effects	T201	UMLS:C1527144
27569995	511	522	scopolamine	T103	UMLS:C0036442
27569995	527	541	administration	T058	UMLS:C1533734
27569995	566	613	group II metabotropic glutamate (mGlu) receptor	T103	UMLS:C0206529
27569995	614	624	antagonist	T103	UMLS:C1254351
27569995	626	634	LY341495	T103	UMLS:C0757826
27569995	636	656	Joint administration	T058	UMLS:C1533734
27569995	683	694	scopolamine	T103	UMLS:C0036442
27569995	750	758	LY341495	T103	UMLS:C0757826
27569995	796	817	antidepressant effect	T033	UMLS:C0243095
27569995	825	845	tail suspension test	T058	UMLS:C0683444
27569995	847	850	TST	T058	UMLS:C0683444
27569995	863	879	forced swim test	T058	UMLS:C0683444
27569995	881	884	FST	T058	UMLS:C0683444
27569995	889	893	mice	T204	UMLS:C0025929
27569995	900	916	drug combination	T103	UMLS:C0013162
27569995	925	938	impair memory	T038	UMLS:C0233794
27569995	962	979	Morris water maze	T058	UMLS:C4277747
27569995	981	984	MWM	T058	UMLS:C4277747
27569995	1013	1031	locomotor activity	T038	UMLS:C0023946
27569995	1035	1039	mice	T204	UMLS:C0025929
27569995	1071	1084	AMPA receptor	T103	UMLS:C0072899
27569995	1085	1095	antagonist	T103	UMLS:C1254351
27569995	1097	1101	NBQX	T103	UMLS:C0045376
27569995	1138	1166	antidepressant-like activity	T033	UMLS:C0243095
27569995	1183	1194	scopolamine	T103	UMLS:C0036442
27569995	1199	1207	LY341495	T103	UMLS:C0757826
27569995	1215	1218	TST	T058	UMLS:C0683444
27569995	1263	1287	para-chlorophenylalanine	T103	UMLS:C0030135
27569995	1289	1293	PCPA	T103	UMLS:C0030135
27569995	1346	1376	serotonergic system activation	T038	UMLS:C1148560
27569995	1384	1411	antidepressant-like effects	T033	UMLS:C0243095
27569995	1429	1440	scopolamine	T103	UMLS:C0036442
27569995	1445	1453	LY341495	T103	UMLS:C0757826
27569995	1470	1493	combined administration	T058	UMLS:C1533734
27569995	1514	1533	antimuscarinic drug	T103	UMLS:C0003385
27569995	1534	1545	scopolamine	T103	UMLS:C0036442
27569995	1554	1576	group II mGlu receptor	T103	UMLS:C0206529
27569995	1577	1587	antagonist	T103	UMLS:C1254351
27569995	1588	1596	LY341495	T103	UMLS:C0757826
27569995	1648	1655	therapy	T058	UMLS:C0087111
27569995	1659	1669	depression	T038	UMLS:C0011570